LoginRegister

    Alembic Pharma Q2 net rises over 1 percent to Rs 121 crore

    Written by Ruby Khatun Khatun   |  

    New Delhi: Alembic Pharmaceuticals reported a 1.44 percent increase in consolidated net profit at Rs 121.56 crore for the second quarter ended September 30, mainly on account of decline in total income.


    The company had posted a net profit of Rs 119.83 crore in the corresponding period of the previous fiscal.


    Total income declined by 9.44 percent to Rs 796.96 crore for the quarter under review against Rs 880.05 crore in the same period a year ago, Alembic Pharmaceuticals said in a BSE filing.



    Alembic Pharmaceuticals MD Pranav Amin said: "The US formulations business continues to face price erosion on some key products, however, the India branded business is showing signs of recovery".

    During the quarter, the company's international formulations business revenue fell 25.56 percent to Rs 262 crore while US formulations business revenue fell 29.36 percent to Rs 190 crore.


    Alembic Pharmaceuticals said its India formulations business grew 6 percent to Rs 385

    Alembic PharmaAlembic PharmaceuticalsFinancial resultsIndiaindian pharma newsnet profitpharma newspharma news indiaPranav Aminsecond quarterTotal income
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X